Jennifer Arnold, COO of Transit Scientific, promoted to President & CEO
April 4, 2024
Transit Scientific is excited to announce that Jennifer Arnold, current COO of Transit Scientific has been promoted to President & CEO of Transit Scientific effective immediately.
Jennifer has been with Transit Scientific for 5+ years, serving in various roles including Vice President of Engineering and Chief Operating Officer. She brings a wealth of knowledge to the role with experience in engineering, regulatory, and supply chain. Jennifer has overseen 7 FDA and 2 CE Mark submissions covering 130+ unique device SKUs with a 100% approval rate to date, currently has 1 patent allowed and 6 patents pending, and was awarded Utah Business’s 40 under 40 business leaders in 2024.
Jennifer comments, “As I transition from Chief Operating Officer to President and CEO, I am deeply honored and excited to take on this new role. With inspired dedication, I look forward to steering Transit Scientific toward continued growth and innovation. Together with our talented team, we will uphold our commitment to advancing healthcare solutions and improving patient outcomes.”
Recent News
- BioSeeker™ Powers Development of a First-of-Its-Kind Programmable Therapeutic for Respiratory Syncytial Virus (RSV)
- Canary Speech Achieves HITRUST e1 Certification for Voice Biomarker Platform
- Recursion Acquires Full Rights to REV102, a Potential First-in-Class Oral ENPP1 Inhibitor for Hypophosphatasia
- Denali Therapeutics Announces FDA Acceptance and Priority Review of Biologics License Application (BLA) for Tividenofusp Alfa for Hunter Syndrome (MPS II)
- GE HealthCare’s Economic Impact Across Utah
- RefloDx Wins Trans Atlantic Angel Grand Prize